Acceleron Pharma Inc (NASDAQ:XLRN) VP Adam M. Veness sold 3,268 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $45.00, for a total value of $147,060.00. Following the completion of the transaction, the vice president now owns 16,925 shares in the company, valued at approximately $761,625. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NASDAQ:XLRN traded down $0.14 during mid-day trading on Monday, reaching $44.32. 233,467 shares of the stock were exchanged, compared to its average volume of 387,584. The company has a 50 day moving average of $41.95. The firm has a market capitalization of $2.32 billion, a PE ratio of -17.11 and a beta of 1.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.11 and a quick ratio of 19.26. Acceleron Pharma Inc has a 1 year low of $37.01 and a 1 year high of $59.59.
Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The company had revenue of $27.67 million for the quarter, compared to analyst estimates of $28.72 million. During the same period in the previous year, the business posted ($0.63) earnings per share. The firm’s revenue was up 649.9% compared to the same quarter last year. Sell-side analysts expect that Acceleron Pharma Inc will post -2.4 EPS for the current fiscal year.
A number of research firms recently issued reports on XLRN. Goldman Sachs Group restated a “neutral” rating and set a $54.00 price target on shares of Acceleron Pharma in a research note on Wednesday, May 29th. Barclays downgraded Acceleron Pharma from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $54.00 to $45.00 in a research note on Friday, May 3rd. ValuEngine upgraded Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday. CIBC restated an “outperform” rating on shares of Acceleron Pharma in a research note on Monday, April 22nd. Finally, Zacks Investment Research restated a “hold” rating on shares of Acceleron Pharma in a research note on Saturday, July 20th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $60.33.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Recommended Story: Insider Trading
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.